- Home
- CUE vs PAVS Comparison
CUE vs PAVS Comparison
Compare CUE & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | PAVS |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.5M | 5.5M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CUE | PAVS |
|---|---|---|
| Price | $36.31 | $4.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $120.00 | N/A |
| AVG Volume (30 Days) | ★ 126.7K | 14.4K |
| Earning Date | 05-13-2026 | 07-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $0.02 |
| 52 Week High | $45.50 | $26.69 |
Technical Indicators
Market Signals| Indicator | CUE | PAVS |
|---|---|---|
| Relative Strength Index (RSI) | 59.76 | 40.16 |
| Support Level | $24.35 | $3.76 |
| Resistance Level | $33.95 | $5.55 |
| Average True Range (ATR) | 2.82 | 0.32 |
| MACD | 0.59 | -0.09 |
| Stochastic Oscillator | 100.00 | 8.71 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd, through its subsidiaries, is involved in the AI-powered entertainment industry, to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It has entered into a software development agreement for the development of 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic. The group is also involved in an e-commerce business and provides TikTok-related e-commerce solutions for customers.